NZ337072A - use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease - Google Patents
use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex diseaseInfo
- Publication number
- NZ337072A NZ337072A NZ337072A NZ33707297A NZ337072A NZ 337072 A NZ337072 A NZ 337072A NZ 337072 A NZ337072 A NZ 337072A NZ 33707297 A NZ33707297 A NZ 33707297A NZ 337072 A NZ337072 A NZ 337072A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nephritis
- patient
- immune complex
- progression
- stabilize
- Prior art date
Links
- 201000008383 nephritis Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000024781 Immune Complex disease Diseases 0.000 title abstract 3
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 title abstract 3
- 208000025883 type III hypersensitivity disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3467397P | 1997-01-10 | 1997-01-10 | |
| PCT/US1997/023482 WO1998030240A1 (en) | 1997-01-10 | 1997-12-31 | Treatment of lupus nephritis with anti-cd40l compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ337072A true NZ337072A (en) | 2000-12-22 |
Family
ID=21877889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ337072A NZ337072A (en) | 1997-01-10 | 1997-12-31 | use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030031668A1 (OSRAM) |
| EP (2) | EP1357131A3 (OSRAM) |
| JP (1) | JP2001508441A (OSRAM) |
| KR (2) | KR20000070034A (OSRAM) |
| CN (2) | CN1572325A (OSRAM) |
| AU (1) | AU5709798A (OSRAM) |
| BR (1) | BR9714523A (OSRAM) |
| CA (1) | CA2277222A1 (OSRAM) |
| CZ (1) | CZ297680B6 (OSRAM) |
| EA (2) | EA200501076A1 (OSRAM) |
| EE (1) | EE9900273A (OSRAM) |
| HU (1) | HUP0000833A3 (OSRAM) |
| IL (1) | IL130784A0 (OSRAM) |
| IS (1) | IS5100A (OSRAM) |
| NO (1) | NO993274L (OSRAM) |
| NZ (1) | NZ337072A (OSRAM) |
| PL (1) | PL190663B1 (OSRAM) |
| TR (7) | TR200001250T2 (OSRAM) |
| WO (1) | WO1998030240A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| HUP0101689A3 (en) * | 1998-04-03 | 2004-08-30 | Trustees Of Darmouth College H | Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease |
| IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| ES2277460T3 (es) | 1998-12-14 | 2007-07-01 | Genetics Institute, Llc | Cadena del receptor de la citoquina. |
| US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
| WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| KR20040023565A (ko) * | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
| ES2390344T3 (es) | 2003-12-23 | 2012-11-12 | Genentech, Inc. | Tratamiento de cáncer con anticuerpos monoclonales anti-IL13 novedosos |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| CN100369932C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人cd154单克隆抗体及其应用 |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| US8435514B2 (en) | 2008-12-05 | 2013-05-07 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| WO2012031122A2 (en) * | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
| CN105722992B (zh) | 2013-09-13 | 2021-04-20 | 豪夫迈·罗氏有限公司 | 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法 |
| MY193481A (en) | 2013-09-13 | 2022-10-17 | Genentech Inc | Method and compositions comprising purified recombinant polypeptides |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| JP2018526443A (ja) * | 2015-08-31 | 2018-09-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
| IL322942A (en) | 2017-05-24 | 2025-10-01 | Als Therapy Development Inst | Therapeutic anti-CD40 ligand antibodies |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| WO1997026000A1 (en) * | 1996-01-16 | 1997-07-24 | The Trustees Of Columbia Univeristy In The City Of New York | Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________ |
| AU2593997A (en) * | 1996-03-21 | 1997-10-10 | Trustees Of Columbia University In The City Of New York, The | Craf1 (traf-3) isoforms and uses thereof |
-
1997
- 1997-12-31 CN CNA2004100353620A patent/CN1572325A/zh active Pending
- 1997-12-31 EP EP03014404A patent/EP1357131A3/en not_active Withdrawn
- 1997-12-31 HU HU0000833A patent/HUP0000833A3/hu unknown
- 1997-12-31 CA CA002277222A patent/CA2277222A1/en not_active Abandoned
- 1997-12-31 TR TR2000/01250T patent/TR200001250T2/xx unknown
- 1997-12-31 EP EP97953325A patent/EP0948355A1/en not_active Withdrawn
- 1997-12-31 CZ CZ0244499A patent/CZ297680B6/cs not_active IP Right Cessation
- 1997-12-31 KR KR1019997006253A patent/KR20000070034A/ko not_active Ceased
- 1997-12-31 WO PCT/US1997/023482 patent/WO1998030240A1/en not_active Ceased
- 1997-12-31 EA EA200501076A patent/EA200501076A1/ru unknown
- 1997-12-31 KR KR1020057013113A patent/KR100618081B1/ko not_active Expired - Fee Related
- 1997-12-31 TR TR2000/01248T patent/TR200001248T2/xx unknown
- 1997-12-31 TR TR2000/01247T patent/TR200001247T2/xx unknown
- 1997-12-31 JP JP53090198A patent/JP2001508441A/ja not_active Ceased
- 1997-12-31 TR TR2000/01246T patent/TR200001246T2/xx unknown
- 1997-12-31 EE EEP199900273A patent/EE9900273A/xx unknown
- 1997-12-31 AU AU57097/98A patent/AU5709798A/en not_active Abandoned
- 1997-12-31 CN CN97181948A patent/CN1247472A/zh active Pending
- 1997-12-31 PL PL97334495A patent/PL190663B1/pl not_active IP Right Cessation
- 1997-12-31 TR TR1999/02191T patent/TR199902191T2/xx unknown
- 1997-12-31 EA EA199900636A patent/EA006314B1/ru not_active IP Right Cessation
- 1997-12-31 TR TR2000/01249T patent/TR200001249T2/xx unknown
- 1997-12-31 TR TR2000/01251T patent/TR200001251T2/xx unknown
- 1997-12-31 BR BR9714523-8A patent/BR9714523A/pt not_active Application Discontinuation
- 1997-12-31 IL IL13078497A patent/IL130784A0/xx unknown
- 1997-12-31 NZ NZ337072A patent/NZ337072A/xx unknown
-
1999
- 1999-06-30 IS IS5100A patent/IS5100A/is unknown
- 1999-07-01 NO NO993274A patent/NO993274L/no not_active Application Discontinuation
-
2002
- 2002-09-27 US US10/260,639 patent/US20030031668A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/527,700 patent/US20070190053A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ337072A (en) | use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease | |
| AU2936395A (en) | Reconstituted human antibody against human interleukin-8 | |
| SI1654287T1 (sl) | Sestavki polipeptidov ki se vežejo na cd | |
| IL103981A (en) | CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| ZA978865B (en) | Reshaped human anti-HM 1.24 antibody. | |
| DK1005870T3 (da) | Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom | |
| ES2132393T3 (es) | Derivados de guanidina utiles en terapeutica. | |
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| WO1999062526A3 (en) | Use of genetically engineered antibodies to cd38 to treat multiple myeloma | |
| NO951903L (no) | Terapeautisk anvendelse av chimeriske og radiomerkede antistoff mot humant B-lymfocyttbegrenset, differensierende antigen for behandling av B-celle lymfom | |
| WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| NZ337073A (en) | use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder | |
| RU2004137823A (ru) | Терапевтическое средство против гиперкальциемического криза | |
| ATE231131T1 (de) | Verbindungen mit wachtumshormon freisetzenden eigenschaften | |
| WO2001037874A3 (en) | Treatment of psoriasis by using an antibody to tnf alpha | |
| EP0339163A3 (en) | Monoclonal antibodies specific for hiv and hybridomas for their production | |
| EP0831869A4 (en) | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | |
| AU3308099A (en) | Method for the treatment of pain, including chronic and female specific pain | |
| MY124071A (en) | Treatment of viral disease in swine | |
| TR199701604T2 (xx) | Pirol t�revleri i�in yeni ba�vuru | |
| ZA922102B (en) | Method of treatment | |
| AU551108B2 (en) | Analgesic potentiation of zomepirac with butorphanol | |
| AU2003230830A8 (en) | Treatment of type 1 diabetes before and after expression of predisposition markers | |
| ATE84069T1 (de) | Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |